Form 4: ALX Oncology CEO Boosts Stake with Stock Purchases

ALX Oncology Holdings Inc. CEO Jason Lettmann acquired 92,233 shares of common stock in open market purchases on September 16 and 17, 2025, increasing his direct beneficial ownership.

Summary

• Jason Lettmann, who serves as both Director and Chief Executive Officer of ALX Oncology Holdings Inc. (ALXO), engaged in open market purchases of the company's common stock.
• On September 16, 2025, Mr. Lettmann acquired 21,070 shares of common stock at a weighted average price of $1.066 per share. These shares were purchased in multiple transactions with prices ranging from $1.05 to $1.07, inclusive.
• On September 17, 2025, he acquired an additional 71,163 shares of common stock at a weighted average price of $1.0805 per share. These shares were purchased in multiple transactions with prices ranging from $1.05 to $1.09, inclusive.
• The total number of shares acquired across both transactions is 92,233, representing an approximate total investment of $99,349.61.
• Following these reported transactions, Mr. Lettmann's direct beneficial ownership in ALX Oncology Holdings Inc. increased to 305,121 shares.

Sentiment

Score: 8

Explanation: The CEO's significant open market purchases of company stock indicate strong confidence in the company's future prospects and current valuation, which is a positive signal for investors.

Positives

• CEO Jason Lettmann's significant open market purchases of 92,233 shares demonstrate strong confidence in ALX Oncology's current valuation and future prospects.
• The investment of approximately $99,349.61 by a key executive aligns management's financial interests more closely with those of shareholders.
• Increased insider ownership can be a positive signal to the market, suggesting that the CEO believes the stock is undervalued or expects positive developments.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The actions of CEO Jason Lettmann in purchasing additional shares reflect a direct expression of confidence in ALX Oncology's prospects and valuation.

Industry Context

Insider buying, particularly by a CEO, is often viewed by the market as a strong signal of management's belief in the company's intrinsic value and future growth potential, especially in the biotechnology sector where R&D milestones and clinical trial results can significantly impact valuation.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this Form 4, significant insider purchases by a CEO, such as Jason Lettmann's acquisition of nearly $100,000 in ALX Oncology stock, generally exceed typical routine open market purchases by executives.
• This level of investment by a top executive is often interpreted as a more robust vote of confidence compared to smaller, more frequent transactions seen across the industry, suggesting a strong conviction in the company's trajectory.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive indicator of management's commitment and belief in the company's long-term value, potentially boosting investor confidence.
• Employees might perceive this as a sign of stability and positive internal outlook, reinforcing morale.

Next Steps

• No specific future actions, events, or milestones are mentioned in this insider transaction report.

Key Dates

Recommendation

The CEO's substantial open market purchases of ALX Oncology stock, totaling nearly $100,000, represent a strong vote of confidence in the company's future. Insider buying, especially from a top executive, often signals that management believes the stock is undervalued or expects significant positive developments. This action aligns management's interests more closely with shareholders and can be a powerful indicator for potential investors.

Keywords

ALX Oncology, ALXO, Insider Buying, CEO Stock Purchase, Jason Lettmann, Form 4, Biotechnology, Oncology